Bausch Health Companies (NYSE:BHC) PT Raised to $9.00 at Piper Sandler

Bausch Health Companies (NYSE:BHC) had its target price increased by analysts at Piper Sandler from $7.00 to $9.00 in a research report issued to clients and investors on Monday, BayStreet.CA reports. The brokerage presently has a “neutral” rating on the stock. Piper Sandler’s target price indicates a potential upside of 2.74% from the company’s previous close.

A number of other brokerages have also recently issued reports on BHC. Royal Bank of Canada lowered their target price on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating for the company in a report on Tuesday, April 23rd. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th. Finally, Jefferies Financial Group dropped their target price on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $11.33.

Bausch Health Companies Stock Down 1.4 %

BHC stock opened at $8.76 on Monday. Bausch Health Companies has a 12 month low of $5.57 and a 12 month high of $11.46. The firm has a market cap of $3.20 billion, a P/E ratio of -5.41 and a beta of 0.85. The company’s 50-day moving average price is $9.31 and its two-hundred day moving average price is $8.19.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.01 by $0.14. The business had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The firm’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.02 EPS. Equities analysts predict that Bausch Health Companies will post 3.95 EPS for the current year.

Hedge Funds Weigh In On Bausch Health Companies

Hedge funds have recently made changes to their positions in the stock. UBS Group AG raised its position in shares of Bausch Health Companies by 127.9% during the third quarter. UBS Group AG now owns 394,232 shares of the company’s stock worth $3,241,000 after acquiring an additional 221,213 shares during the last quarter. Readystate Asset Management LP bought a new position in shares of Bausch Health Companies during the fourth quarter worth about $2,933,000. Deutsche Bank AG raised its position in shares of Bausch Health Companies by 1,397.8% during the third quarter. Deutsche Bank AG now owns 362,850 shares of the company’s stock worth $2,983,000 after acquiring an additional 338,624 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Bausch Health Companies by 1.6% during the third quarter. Vanguard Group Inc. now owns 11,487,768 shares of the company’s stock worth $94,429,000 after acquiring an additional 175,489 shares during the last quarter. Finally, Segantii Capital Management Ltd raised its position in shares of Bausch Health Companies by 20.0% during the third quarter. Segantii Capital Management Ltd now owns 3,000,000 shares of the company’s stock worth $24,660,000 after acquiring an additional 500,000 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.